In primary bovine aortic endothelial cells, hesperetin increased Akt, AMPK and eNOS phosphorylation and NO-sensitive fluorescence. The response to 10 μM hesperetin for 10 min was inhibited by L-NAME or wortmannin. These cellular findings do not establish direct kinase binding or human efficacy. [3]
Competitive inhibition of tissue-derived PDE4
Biochemical assay · PDE4 activity in guinea-pig lung or heart homogenate; Figure 1 does not distinguish the tissue source [1]
Hesperetin inhibited cAMP hydrolysis with kinetics interpreted by the authors as competitive. Rolipram served as a reference inhibitor. This experiment does not establish PDE-family or PDE4-subtype selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10, 30 and 100 μM hesperetin
- Exposure duration
- 30 min enzyme incubation at 37°C
- Method
- Radiometric cAMP-hydrolysis assay; Lineweaver–Burk analysis
- Vehicle
- Hesperetin stock dissolved in ethyl alcohol:DMSO (1:1); final assay solvent fraction not specified
- Reported limits
- Exact lung versus heart contribution and biological independence of n are not specified for Figure 1.
Methods and source locations
Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)
Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.
Methods 2.1–2.2 and 2.6; Results 3.1; Figure 1a–b and caption
Inhibition of PDE4-catalyzed cAMP hydrolysis: Apparent Km versus inhibitor concentration, Figure 1a inset — Results 3.1; Figure 1a inset; Methods 2.6
Reference inhibitor rolipram in the same assay: Same kinetic analysis — Results 3.1; Figure 1b inset; Methods 2.6
Weak PTP1B inhibition by hesperetin aglycone
Biochemical assay · Human recombinant PTP1B assayed with p-nitrophenyl phosphate [2]
Hesperetin was a weak inhibitor under this assay, with a substantially higher reported IC50 than the positive control ursolic acid. More active glycosides in this paper are different materials.
Literature-Reported Treatment Conditions
- Exposure duration
- 10 min preincubation, followed by 20 min substrate reaction at 37°C
- Method
- pNPP hydrolysis; absorbance at 405 nm
- Vehicle
- Sample described as dissolved in 10% DMSO; final DMSO fraction not separately stated
- Reported limits
- Full IC50 dose series is not tabulated in the selected sections. IC50 is an assay endpoint, not a cell-treatment dose.
Methods and source locations
Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)
Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.
Results 2.1; Table 1 hesperetin and ursolic acid rows and footnote a,d; Methods 4.1–4.2, 4.5
PTP1B inhibition by hesperetin: Log dose-inhibition curve; enzyme-free hydrolysis correction; ursolic acid positive control — Table 1 hesperetin row and footnote a; Methods 4.2
PTP1B inhibition by positive-control ursolic acid: Same assay — Table 1 ursolic acid row and footnotes a,d
Acute endothelial signaling and nitric oxide production
Cell-based study · Primary bovine aortic endothelial cells (BAEC), passages 3–5, serum-starved overnight [3]
Hesperetin increased Akt, AMPK and eNOS phosphorylation and the NO-sensitive fluorescent signal. L-NAME and wortmannin blocked the NO response; insulin and LPA provided pathway controls. This is a cellular response, not proof of direct kinase activation or human efficacy.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 0.01, 0.1, 1 and 10 μM for concentration series; 10 μM for time series and inhibitor-control experiment
- Exposure duration
- 10 min for concentration series; 0, 1, 5, 10, 15 and 30 min for time series
- Method
- Immunoblotting and DAF-2-DA fluorescence in fixed BAEC
- Co-treatment
- For control experiments: L-NAME (100 μM) or wortmannin (100 nM), added 30 min before dye loading; insulin and LPA are comparator stimuli, not hesperetin combinations used to claim synergy.
- Reported limits
- Vehicle, hesperetin supplier/purity and enantiomer composition are not specified in the read main-text sections; Supplemental Data were not retrieved.
Methods and source locations
Compound reported in the paper: Hesperetin; Compound label in the paper: Hesperetin (paper material; stereochemistry unspecified)
Evidence concerns the reported hesperetin preparation at the aglycone identity level; no enantiomer-specific or supplier-lot performance claim.
Subjects and Methods: In vitro experiments; Results: Hesperetin acutely stimulates phosphorylation; Figure 1A–D and complete caption
Phospho-Akt Ser473, phospho-AMPK Thr172 and phospho-eNOS Ser1179: Immunoblots with β-actin loading control; five to six independent repeats, caption; densitometry mean ± SEM — Figure 1A–B and caption
NO-sensitive fluorescence after hesperetin and inhibitor controls: DAF-2-DA; concentration/time images repeated independently three times; inhibitor-control experiment five times, caption — Figure 1C–D and caption